Pfizer инвестирует в начинающие компании 600 млн дол

09 June 2018

Илья Дугин / Фармацевтический вестник

Американская фармацевтическая компания Pfizer объявила о намерении инвестировать в начинающие биотехнологические компании 600 млн долл., из которых 25% пойдет на разработку лекарственных препаратов для лечения неврологических заболеваний, сообщает FirstWord Pharma.

Инвестиции будут осуществляться через подразделение Pfizer – Pfizer Ventures.

Средства предназначены для поддержки перспективных биотехнологических компаний, специализирующихся на ранних стадиях разработки лекарственных препаратов, в т.ч. в области неврологии.


Previous publication Next publication

Media Center

  • 23 October 2018

    Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients

    Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies of its Oncotype DX® tests highlighting their value in optimizing treatment for patients with various stages of breast and prostate cancer. The findings, presented at the ESMO 2018 Congress in Munich, Germany, demonstrated that the Oncotype DX tests identify patients who will or will not benefit from a specific treatment.

  • 23 October 2018

    Russian cancer drug based on smallpox vaccine undergoes preclinical studies

    Siberian scientists have brought to the final stage of preclinical testing the only Russian therapeutic cancer drug. This part of the study is expected to be completed by the end of 2019, according to Sergei Netesov, Chairman of the Board of the Association for the Development of the Innovative Territorial Cluster of the Novosibirsk Region in the Sphere of Biopharmaceutical Technologies (‘Biopharm’).

  • 22 October 2018

    Pfizer preps for BMS showdown with Bavencio kidney cancer combo data

    Pfizer has long been a player in kidney cancer, but it’s looking to take things up a notch—and challenge next-gen rival Bristol-Myers Squibb—with its latest data. Sunday at the European Society for Medical Oncology annual meeting, the New York drugmaker and partner Merck KGaA said their immuno-oncology agent Bavencio, in tandem with Pfizer’s Inlyta, had staved off cancer progression in previously untreated patients by a median 13.8 months, compared with 8.4 months for standard-of-care Sutent, another Pfizer drug.

  • 19 October 2018

    FDA Publishes Guidance on the Rare Disease Treatments

    FDA published draft guidance on October 15, 2018 to assist sponsors developing treatments for rare diseases plan for pre-investigational new drug application (pre-IND) meetings with FDA. In the guidance, the agency describes topics that should be considered in early drug development and pre-IND meetings.

Read more